Ken Griffin Ideaya Biosciences, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$30.37 - $43.05 $54,666 - $77,490	-1,800 Reduced 21.18%	6,700 $212,000
Q2 2024 Aug 14, 2024	BUY	$34.37 - $43.46 $206,219 - $260,760	6,000 Added 240.0%	8,500 $298,000
Q1 2024 May 15, 2024	SELL	$34.2 - $47.13 $47,880 - $65,982	-1,400 Reduced 35.9%	2,500 $109,000
Q4 2023 Feb 14, 2024	SELL	$24.59 - $35.83 $137,704 - $200,648	-5,600 Reduced 58.95%	3,900 $138,000
Q3 2023 Nov 14, 2023	SELL	$21.07 - $29.77 $4,214 - $5,954	-200 Reduced 2.06%	9,500 $256,000
Q2 2023 Aug 14, 2023	BUY	$13.33 - $25.53 $129,301 - $247,641	9,700 New	9,700 $227,000
Q4 2022 Feb 14, 2023	BUY	$14.47 - $18.17 $5,788 - $7,268	400 New	400 $7,000

216

80.8M

69K

20K

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.3B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.